




PHARMACEUTICAL 2023

Schrodinger Inc.
Rank 172 of 446





RealRate

PHARMACEUTICAL 2023

Schrodinger Inc.
Rank 172 of 446



The relative strengths and weaknesses of Schrodinger Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Schrodinger Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 38% points. The greatest weakness of Schrodinger Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 134%, being 90% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	533,989
Cost of Goods Sold	79,933
Intangible Assets	5,378
Liabilities, Current	108,799
Liabilities, Non-Current	131,883
Other Assets	134,976
Other Compr. Net Income	-1,728
Other Expenses	30,705
Other Liabilities	0
Other Net Income	-2,309
Other Revenues	180,955
Property and Equipment	14,244
Research and Development	126,372
Selling, General and Administrative Expense	90,825

Output Variable	Value in 1000 USD
Assets	688,587
Liabilities	240,682
Expenses	327,835
Revenues	180,955
Stockholders Equity	447,905
Net Income	-149,189
Comprehensive Net Income	-150,053
Economic Capital Ratio	134%